Work

“Development of the Proteasome Inhibitor Velcade™ (Bortezomib)” by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D

Year: 2004

Type: editorial

Abstract: Drs. Adams and Kauffman have provided a detailed history of the development of the novel cancer therapeutic agent Velcade™ (bortezomib). This is a thorough discussion of the preclinical studies exa...

Source: Cancer Investigation

DOI: 10.1081/cnv-120030223

Author: Richard Bold

Institutions: University of California Davis Medical Center, UC Davis Comprehensive Cancer Center

Language: English

Topic: Ubiquitin and proteasome pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2000906764

Cites: 4

Cited by: 22

Related to: 10